Makhmudova U, Schulze PC, Davis HR, Weingärtner O. Lipid lowering in patients 75 years and older. World J Cardiol 2021; 13(10): 526-532 [PMID: 34754397 DOI: 10.4330/wjc.v13.i10.526]
Corresponding Author of This Article
Oliver Weingärtner, MD, PhD, Adjunct Professor, Klinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany. oliver.weingaertner@med.uni-jena.de
Research Domain of This Article
Cardiac & Cardiovascular Systems
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Cardiol. Oct 26, 2021; 13(10): 526-532 Published online Oct 26, 2021. doi: 10.4330/wjc.v13.i10.526
Lipid lowering in patients 75 years and older
Umidakhon Makhmudova, P Christian Schulze, Harry R Davis, Oliver Weingärtner
Umidakhon Makhmudova, P Christian Schulze, Oliver Weingärtner, Klinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany
Harry R Davis, Synergy Partners RD Solutions, Synergy Partners RD Solutions, Gaithersburg, MD 20850, United States
Author contributions: Makhmudova U, Schulze PC, Davis HR and Weingärtner O wrote the manuscript and designed figures; All authors have read and approved the final manuscript.
Conflict-of-interest statement: The authors declare that there are no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Oliver Weingärtner, MD, PhD, Adjunct Professor, Klinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany. oliver.weingaertner@med.uni-jena.de
Received: April 1, 2021 Peer-review started: April 1, 2021 First decision: July 6, 2021 Revised: July 12, 2021 Accepted: September 8, 2021 Article in press: September 8, 2021 Published online: October 26, 2021 Processing time: 201 Days and 15.4 Hours
Abstract
More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date – ezetimibe. Since then, ezetimibe has become a well-recognized player in lipid-lowering therapy. Recent findings of IMPROVE-IT and EWTOPIA 75 imply that elderly patients over the age of 75 years in particular benefit from ezetimibe. This review summarizes the evidence, discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines.
Core Tip: The review summarizes the evidence of lipid-lowering therapies in patients 75 years and older, and discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines.
